Cryptococcal meningitis, a fungal infection caused by Cryptococcus spp., is one of the most important HIV-related opportunistic infections. In countries with a high HIV/AIDS prevalence, Cryptococcus is one of the most common causes of meningitis overall, more frequent than Streptococcus pneumoniae or Neisseria meningitidis[1–7]. Following the introduction of combination antiretroviral therapy (ART), the incidence of cryptococcosis has declined substantially in North America and Western Europe [8–11].
Understanding the burden of cryptococcal disease is particularly important for public health officials to adequately plan and prioritize needed resources for disease prevention and control. To better define the burden of cryptococcal meningitis, as it relates to other important diseases, and to understand the need for public health attention to this infection, we reviewed available epidemiological data and estimated the global burden of cryptococcal meningitis among persons living with HIV.
Cryptococcal meningitis incidence data
We searched the published medical literature in November 2007 for eligible articles, using the search terms ‘HIV’ or ‘AIDS’ and ‘opportunistic infection,’ and limiting to studies published in English during or after 1996. An eligible article was one that utilized a prospective or retrospective cohort study design, was conducted in relatively varied heathcare settings (e.g., hospitalized and outpatient), and reported an incidence among persons with HIV or reported results from which incidence rates among persons with HIV could be calculated.
Our initial literature search yielded 9032 references. From these, we identified 19 studies that met our eligibility criteria [8–10,12–27]. Of the 19 studies, seven were population-based studies of large geographically defined areas [8,12,14,15,26,27]. The remaining 12 were provider-based studies that were not defined by geography [9,13,16–25].
Eleven studies directly reported an estimated incidence and in three [9,13,14] the incidence was determined based on data provided in a figure in the original article. For five population-based studies [8,10,12,15,27], the number of cases was reported but the incidence among persons with HIV was not. For three of these studies [8,12,15], we calculated the incidence rates in these areas using the number of cases reported as a numerator and using an available estimate for the total HIV population as a denominator. In one of these three , this numerator was the average yearly number of cases during the years of the surveillance, and, for the other two, we used the estimate for the final year of the study. For denominators, one study reported an estimate in the text , and, in another , we used a national surveillance report , and in the third , we used the 2007 United Nations Programme on HIV/AIDS (UNAIDS) estimate . We excluded the other two population-based studies [10,27], because we were unable to determine the HIV population.
Global HIV population data
The global population of persons living with HIV was taken from the estimate for prevalent cases of HIV among adults and children as reported in the 2007 UNAIDS report (33 200 000 cases) [29,30]. A separate HIV population estimate was taken for each of the UNAIDS regions.
Regional and global estimates
We used the median incidence rate from the available studies of a geographic region, as defined by UNAIDS, to estimate the region-specific cryptococcal meningitis incidence. For regions with no available incidence data, we imputed the rate using the median from a region that is both geographically proximal and similar in economic development. Estimates of cryptococcal meningitis burden for each region i (CMi) were calculated by multiplying the median incidence rate by the 2007 UNAIDS HIV population estimate for each region . The global burden estimate for cryptococcal meningitis was defined as the sum of all regional estimates.
The range of cases in each region was calculated as ±1 standard deviation (SD) from the regional estimate, in which the region-specific standard deviation SDi was defined as
ĈV, was the median coefficient of variation of available region-specific CVis, and CMi was the estimate for cryptococcal meningitis cases in the region i. To determine ĈV, we first calculated the coefficient of variation (CVi) for each region with at least two available and differing data points using the median incidence and a robust estimate of scale based on the interquartile range. Because region-specific incidences were sparse, we pooled information across regions to estimate a common measure of variability, the median coefficient of variation (ĈV). This median coefficient of variation (ĈV) was then applied to each region to calculate the region-specific SDi. The estimation of SDi ignores the variability inherent in the estimate of the HIV counts. The SD for the global estimate was calculated as the square root of the sum of the squared SDis.
Estimating case fatality
Because mortality is likely to vary regionally, we estimated deaths by using case-fatality rates from clinical trials conducted in developed and less-developed countries [31,32], by reviewing case series, surveillance reports, and reports on outcomes of cryptococcal meningitis [1,5,10,16,26,31,33–39], and by consulting with clinical experts (N.G., P.G.P.) in the care and outcomes of cryptococcal meningitis. In regions with primarily developed countries, we assumed a 10-week case-fatality rate of 9% among infected persons. Case fatality was estimated to be 55% in regions with primarily less-developed countries, excluding sub-Saharan Africa, where it was estimated to be 70%.
Incidence reported in all studies ranged from 0.04 to 12% per year (Table 1). At least one eligible study was available from all regions except Eastern Europe and Central Asia; North Africa and Middle East; and the Caribbean. For these three regions, incidence rates were imputed: the rate in Eastern Europe and Central Asia, and North Africa and Middle East, were assumed to be the same as East Asia (1.7% per year). The incidence in the Caribbean was assumed to be the same as Latin America (3.4% per year).
Using these rates, we estimated 957 900 (range, 371 700–1.54 million) cryptococcal meningitis cases occurred in 2006 (Table 1). The region with the highest number of estimated cases was sub-Saharan Africa (720 000 cases; range, 144 000–1.3 million), followed by South and South-east Asia (120 000 cases; range, 24 000–216 000). Oceania (100 cases), Western and Central Europe (500 cases), North Africa and Middle East (6500 cases), and North America (7800 cases) were the regions with the fewest.
On the basis of these estimates and the estimates of case fatality outlined above, approximately 624 725 deaths (range, 124 956–1,124 494) were associated with cryptococcal meningitis (Table 1); Oceania is estimated to have had the fewest (nine deaths), whereas sub-Saharan Africa had the most (504 000; range, 100 800–907 200). When comparing the estimate of deaths in sub-Saharan Africa with other diseases excluding HIV, deaths associated with cryptococcal meningitis are higher than tuberculosis (350 000) and approach the number related to childhood-cluster diseases (pertussis, poliomyelitis, diphtheria, measles, and tetanus, 530 000 deaths combined), diarrheal diseases (708 000), and malaria (1.1 million) (Fig. 1) .
On the basis of review of available epidemiological data, we estimate a very substantial global burden of cryptococcal meningitis, both in terms of numbers of infections and associated deaths. These estimates will be useful for public health officials in designing and prioritizing efforts to prevent, diagnose, and treat cryptococcal disease.
The worldwide number of infections and deaths due to cryptococcal meningitis appear similar to those for diseases that have received greater public health attention. In sub-Saharan Africa, deaths due to cryptococcal meningitis (530 000) may be more frequent than tuberculosis (350 000) .
Our estimates of global disease burden are limited by the number of available studies in the literature and by the limitations of the original studies themselves. Provider-based cohort studies may not be representative of the region as a whole, and larger, population-based studies may be limited by incomplete follow-up or case ascertainment. For example, in one of the population-based studies from South Africa, the incidence was much lower than other studies from sub-Saharan Africa, likely due to incomplete case ascertainment .
We assumed case-fatality rates based on reviewing reports from clinical trials, surveillance studies, and expert opinion. Despite these assumptions, we feel that the number of deaths is fairly accurate, particularly in sub-Saharan Africa, as our estimate is consistent with what would be calculated from HIV cohort and natural history studies. These studies report that 13–44% of HIV/AIDS deaths are due to Cryptococcus[16,38,41]. If 2094 996 HIV/AIDS deaths occur annually in sub-Saharan Africa , then annual Cryptococcus-related deaths should range from 272 349 to 921 798.
Many of the incidence estimates used here were determined prior to the current effort to provide wide access to antiretroviral treatment. However, as the number of persons still needing antiretroviral drugs is likely to be stable or even increasing, due to the evolution of the HIV epidemic in many of these areas, expanding access to ART is not likely to impact the global burden of cryptococcal disease soon. In fact, rates of cryptococcal meningitis in South Africa have actually increased since the introduction of antiretroviral therapy , thereby emphasizing the growing and future need for attention to this problem.
In many of the developing countries in sub-Saharan Africa and South and South-east Asia, the capacity to perform the complicated management of severe cryptococcal meningitis is limited . An important step in reducing the impact of this infection undoubtedly is the marked expansion of ARV access therapy for HIV, as risk of cryptococcal disease is substantially reduced among persons receiving these treatments. However, because the numbers of people with advanced immunosuppression from HIV and cryptococcal disease will continue to remain high despite expanded access to antiretroviral therapy, specific public health efforts are needed.
One such effort should be the expansion of laboratory diagnostic capacity for cryptococcal meningitis, such as India ink staining of cerebral spinal fluid, and the cryptococcal antigen latex agglutination test, which is simple to use, has high sensitivity and specificity , and requires little training for the proper use and interpretation.
Prevention of disease is the ultimate public health goal in the approach to cryptococcal meningitis, though this may be difficult to achieve. Although most clinical trials did not show a survival benefit [45–48], additional clinical trials are warranted, especially in sub-Saharan Africa, where the incidence of cryptococcal meningitis is high and outcomes of infection are poor. Another strategy that warrants further investigation is screening for early cryptococcal disease with the serum cryptococcal antigen test. Nonmeningeal cryptococcal infection often precedes meningitis but is underrecognized or misdiagnosed [16,35,49–51]. Early detection and treatment of asymptomatic or latent cryptococcal infection may allow for fluconazole to be used as the first-line therapy, a much less expensive and highly available option.
Our findings underscore the tremendous burden of cryptococcal meningitis, as well as the critical need for a better understanding of its epidemiology in developing countries with large numbers of persons living with HIV/AIDS. A focused effort to improve diagnostic capacity, expand treatment options, and identify effective measures for prevention of cryptococcal disease is urgently needed.
The findings and conclusions in this presentation/report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
This information is distributed solely for the purpose of predissemination peer review under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention. It does not represent and should not be construed to represent any agency determination or policy.
Funding source: This study was conducted while being employed by the US Government; no external funds were used for this study.
P.G.P. has received a research grant, is a member of speakers' bureau, and is an ad hoc advisor (Pfizer, Merck, Astellas) and has received a research grant and is an ad hoc advisor (Schering-Plough).
B.J.P., K.A.W., B.J. M., N.G., T.M.C. have no conflicts of interest.
Conception and design were done by B.J.P., K.A.W., B.J.M., N.G., P.G.P., T.M.C.
Acquisition of data was done by B.J.P., K.A.W.
Analysis and interpretation of data was done by B.J.P., K.A.W., B.J.M., N.G., P.G.P., T.M.C.
Drafting of manuscript was done by B.J.P., K.A.W., B.J.M., T.M.C.
Critical review of manuscript was done by B.J.P., K.A.W., B.J.M., N.G., P.G.P., T.M.C.
Statistical analysis was done by B.J.P., K.A.W.
1. Bekondi C, Bernede C, Passone N, Minssart P, Kamalo C, Mbolidi D, Germani Y. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis 2006; 10:387–395.
2. Bogaerts J, Rouvroy D, Taelman H, Kagame A, Aziz MA, Swinne D, Verhaegen J. AIDS
-associated cryptococcal meningitis
in Rwanda (1983–1992): epidemiologic and diagnostic features. J Infect 1999; 39:32–37.
3. Gordon SB, Walsh AL, Chaponda M, Gordon MA, Soko D, Mbwvinji M, et al
. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis 2000; 31:53–57.
4. Helbok R, Pongpakdee S, Yenjun S, Dent W, Beer R, Lackner P, et al
. Chronic meningitis in Thailand. Clinical characteristics, laboratory data and outcome in patients with specific reference to tuberculosis and cryptococcosis. Neuroepidemiology 2006; 26:37–44.
5. Heyderman RS, Gangaidzo IT, Hakim JG, Mielke J, Taziwa A, Musvaire P, et al
. Cryptococcal meningitis
in human immunodeficiency virus-infected patients in Harare, Zimbabwe [see comment]. Clin Infect Dis 1998; 26:284–289.
6. Hovette P, Soko TO, Raphenon G, Camara P, Burgel PR, Garraud O. Cryptococcal meningitis
patients: an emerging opportunistic infection in Senegal. Trans R Soc Trop Med Hyg 1999; 93:368.
7. Schutte CM, Van der Meyden CH, Magazi DS. The impact of HIV
on meningitis as seen at a South African Academic Hospital (1994 to 1998). Infection 2000; 28:3–7.
8. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O, French Cryptococcosis Study G. Epidemiology
-associated cryptococcosis in France (1985–2001): comparison of the pre and post-HAART eras [see comment]. AIDS
9. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al
of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl 1):S5–S14.
10. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, et al
. The changing epidemiology
of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. Clin Infect Dis 2003; 36:789–794.
11. van Elden LJ, Walenkamp AM, Lipovsky MM, Reiss P, Meis JF, de Marie S, et al
. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS
12. Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994–1998: regional variation and temporal trends. Clin Infect Dis 2001; 32:955–962.
13. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, et al
. Changing incidence of central nervous system diseases in the EuroSIDA cohort [see comment]. Ann Neurol 2004; 55:320–328.
14. Dilley JW, Schwarcz S, Loeb L, Hsu L, Nelson K, Scheer S. The decline of incident cases of HIV
-associated neurological disorders in San Francisco, 1991–2003. AIDS
15. Dore GJ, Li Y, McDonald A, Ree H, Kaldor JM; National HIV
Surveillance Committee. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia
. J Acquir Immune Defic Syndr
:388–395. [Erratum appears in J Acquir Immune Defic Syndr
:368; note: Kaldo, John M (corrected to Kaldor, John M)]. J Acquir Immune Defic Syndr
16. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al
. Cryptococcal infection in a cohort of HIV
-1-infected Ugandan adults. AIDS
17. Kim JM, Cho GJ, Hong SK, Chang KH, Chung JS, Choi YH, et al
and clinical features of HIV
in Korea. Yonsei Med J 2003; 44:363–370.
18. Klotz SA, Nguyen HC, Van Pham T, Nguyen LT, Ngo DT, Vu SN. Clinical features of HIV
patients presenting to an inner city clinic in Ho Chi Minh City, Vietnam. Int J STD AIDS
19. Kong BN, Harwell JI, Suos P, Lynen L, Mohiuddin S, Reinert S, Pugatch D. Opportunistic infections and HIV
clinical disease stage among patients presenting for care in Phnom Penh, Cambodia. Southeast Asian J Trop Med Public Health 2007; 38:62–68.
20. Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis 2003; 36:79–85.
21. Mbanya DN, Zebaze R, Minkoulou EM, Binam F, Koulla S, Obounou A. Clinical and epidemiologic trends in HIV
patients in a hospital setting of Yaounde, Cameroon: a 6-year perspective. Int J Infect Dis 2002; 6:134–138.
22. Oh F MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, et al
. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis 1999; 29:1524–1528.
23. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al
-associated neurologic disease incidence changes: multicenter AIDS
cohort study, 1990–1998. Neurology 2001; 56:257–260.
24. Vajpayee M, Kanswal S, Seth P, Wig N. Spectrum of opportunistic infections and profile of CD4+ counts among AIDS
patients in North India. Infection 2003; 31:336–340.
25. Wolff MJ, Beltran CJ, Vasquez P, Ayala MX, Valenzuela M, Berrios G, Arredondo A. The Chilean AIDS
cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country – organization and preliminary results. J Acquir Immune Defic Syndr 2005; 40:551–557.
26. McCarthy KM, Morgan J, Wannemuehler KA, Mirza SA, Gould SM, Mhlongo N, et al
. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV
27. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, et al
. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group [see comment]. J Infect Dis 1999; 179:449–454.
28. NCHECR, HIV
, Hepatitis C, and Sexually Transmitted Infections in Australia. Annual Surveillance Report 2000. 2000; The University of New South Wales: Sydney, NSW, Australia.
29. UNAIDS. 2006 report on the global AIDS
epidemic. 2006; pp. 502–540. http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp
31. Mayanja-Kizza H, Oishi K, Mitarai S, Yamashita H, Nalongo K, Watanabe K, et al
. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis
in Ugandan patients with AIDS
[see comment]. Clin Infect Dis 1998; 26:1362–1366.
32. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al
. Treatment of cryptococcal meningitis
associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS
Clinical Trials Group [see comment]. N Engl J Med 1997; 337:15–21.
33. Gumbo T, Kadzirange G, Mielke J, Gangaidzo IT, Hakim JG. Cryptococcus
neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2002; 21:54–56.
34. Khanna N, Chandramuki A, Desai A, Ravi V, Santosh V, Shankar SK, Satishchandra P. Cryptococcosis in the immunocompromised host with special reference to AIDS
. Indian J Chest Dis Allied Sci 2000; 42:311–315.
35. Lara-Peredo O, Cuevas LE, French N, Bailey JW, Smith DH. Cryptococcal infection in an HIV
-positive Ugandan population. J Infect 2000; 41:195.
36. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, et al
. Long-term outcome of AIDS
-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS
37. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, Zumla A. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis
in Zambian AIDS
patients treated under local conditions. Postgrad Med J 2001; 77:769–773.
38. Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV
-1) natural history cohort in Uganda. Int J Epidemiol 1998; 27:698–702.
39. Sun HY, Chen MY, Hsiao CF, Hsieh SM, Hung CC, Chang SC. Endemic fungal infections caused by Cryptococcus
neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active antiretroviral therapy. Clin Microbiol Infect 2006; 12:381–388.
40. WHO. Revised Global Burden
of Disease (GBD) 2002 Estimates. 2002. http://www.who.int/healthinfo/bodgbd2002revised/en/index.html
41. Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al
. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251–1258.
42. Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa (GERMS-SA), GERMS-SA Annual Report 2007; 2007.
43. Hamill RJ. Free fluconazole for cryptococcal meningitis
: too little of a good thing? [comment]. Clin Infect Dis 2006; 43:1074–1076.
44. Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994; 32:1680–1684.
45. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34:277–284.
46. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al
. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28:1049–1056.
47. Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, et al
. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS
Clinical Trials Group [see comment]. N Engl J Med 1995; 332:700–705.
48. Smith DE, Bell J, Johnson M, Youle M, Gazzard B, Tchamouroff S, et al
. A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV
Med 2001; 2:78–83.
49. Driver JA, Saunders CA, Heinze-Lacey B, Sugar AM. Cryptococcal pneumonia in AIDS
: is cryptococcal meningitis
preceded by clinically recognizable pneumonia? J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:168–171.
50. Wong ML, Back P, Candy G, Nelson G, Murray J. Cryptococcal pneumonia in African miners at autopsy. Int J Tuberculosis Lung Dis 2007; 11:528–533.
51. Tassie JM, Pepper L, Fogg C, Biraro S, Mayanja B, Andia I, et al
. Systematic screening of cryptococcal antigenemia in HIV
-positive adults in Uganda. J Acquir Immune Defic Syndr 2003; 33:411–412.